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Discussion
•

In regards to increasing our
Naloxone Co-prescribing,
we had 2 major findings:

•

“I really think leadership is a big part of the
success. [The medical director] has been a
driving force to normalize this treatment and
breakdown any biases that staff would have. Our
practice manager is an expert at utilizing state
funded resources. She took on getting the state
supplied [Naloxone] doses as soon as she found
out about them. She similarly was instrumental
in making us an opiate health home. And again
we have always had a culture of involving MAs in
quality endeavors and asking them to take
ownership.” – WCMP Provider

Introduction
•
•
•

Naloxone availability and administration saves lives
The CDC recommends naloxone co-prescribing for patients with OUD and other
eligibility criteria
Maine Medical Center’s baseline was found to be 6% in one clinic. This held true
across the entire MaineHealth system.

Methods
1.

In 2017, we started monitoring Naloxone Co-prescribing rates quarterly on
an individual subsystem basis, stratifying by indication diagnosis listed in
the EMR. Indication diagnoses were limited to:
•
•
•

OUD
Concurrent Benzo Rx
Concurrent Sedative Rx

•
•
•

>50MME/day Opioid Script
History of other SUD
History of Overdose

2. Simultaneously, we conducted a series of PDSA cycles based on the following
interventions:
1.
2.
3.
4.
5.

Implementation of Naloxone standing order (Q2 2017)
Providing on-site training (Q3 2017)
Development of MaineHealth Opioid Prescribing Guidelines (Q3 2018)
Development of online educational modules (Q3 2018)
Implementation of a Best-Practice Advisory that will appear with
opioid/MOUD order in eligible patients (Q3 2019)

3. With each cycle, we evaluated the impact it had on Naloxone co-prescribing
both system-wide as well as within each individual subsystem

Results
•
•
•
•
•

1. Our most effective
system-wide change was to
implement a Best Practice
Advisory in the EMR.

The Hierarchy of Controls is a concept in Process Improvement that postulates the
effectiveness of an intervention is proportional to the amount of control it has on human
behavior.
A common metaphor is a railroad crossing. Educating automobile drivers will have the
least likelihood of reducing car-train accidents. Mitigation with warning signs will have an
increasing effect. Facilitation with a railroad crossing arm will exponentially increase
safety. But nothing comes close to Elimination of the problem, represented in building a
tunnel for the automobiles to drive underneath the train tracks.

MAJOR FINDINGS
BPA was associated with greatest overall change system wide – 12%
In 2018, Western Maine Health (WMHP) identified Naloxone as an AIP goal. Led to
largest individual subsystem change – 30%
MINOR FINDINGS
Online Educational Modules/Guidelines had a significant but less substantial impact
– 7%

Fig 1. Effects on System-Wide Naloxone Co-prescribing

Fig 2. WMHP AIP Leads to Dramatic Rise in Co-Prescribing

Our findings demonstrated that interventions higher on the Hierarchy of Control
(see diagram and description below have a greater impact on process
improvement than educational efforts.
Additionally, when we stratified the data, we found that WCMP had an
anomalous rise in their naloxone co-prescribing rates, independent from our
system-wide actions. This prompted our team to conduct a series of interviews
with WMCP leadership and providers. We found that the entire team, from front
line providers/staff to leadership, identified that naloxone co-prescribing was
important to them (many because of the impact of opioid overdose they all saw in
their community). Below is an excerpt from one such interview:

Figure is presented courtesy of the Institute for Healthcare Improvement

2. The most effective
individual change happened
when the entire Western
Maine system valued coprescribing and frontline
staff were empowered to
change it.

Supplemental Graphs
•

Supplemental Data can be viewed at the QR Code below

Or can be viewed by clicking here
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